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Abstract 55 
Scope 56 
Antimicrobial stewardship interventions and programmes aim to ensure effective treatment 57 
while minimising antimicrobial-associated harms including resistance. Practice in this vital 58 
area is undermined by the poor quality of research addressing both what specific 59 
antimicrobial use interventions are effective and how antimicrobial use improvement 60 
strategies can be implemented into practice. In 2016 we established a working party to 61 
identify the key design features which limit translation of existing research into practice and 62 
then to make recommendations for how future studies in this field should be optimally 63 
designed. The first part of this work has been published as a systematic review. Here we 64 
present the working group’s final recommendations.  65 
Methods 66 
An international working group for design of antimicrobial stewardship intervention 67 
evaluations was convened in response to the fourth call for leading expert network 68 
proposals by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). The 69 
group comprised clinical and academic specialists in antimicrobial stewardship and clinical 70 
trial design from six European countries. Group members completed a structured 71 
questionnaire to establish the scope of work and key issues to develop ahead of a first face-72 
to-face meeting which 1) identified the need for a comprehensive systematic review of 73 
study designs in the literature and 2) prioritised key areas where research design 74 
considerations restrict translation of findings into practice. The working group’s initial 75 
outputs were reviewed by  independent advisors and additional expertise was sought in 76 
specific clinical areas. At a second face-to-face meeting the working group developed a 77 
  5
theoretical framework and specific recommendations to support optimal study design. 78 
These were finalised by the working group co-ordinators and agreed by all working group 79 
members 80 
Recommendations 81 
We propose a theoretical framework in which consideration of the intervention rationale 82 
the intervention setting, intervention features and the intervention aims inform selection 83 
and prioritization of outcome measures, whether the research sets out to determine 84 
superiority or non-inferiority of the intervention measured by its primary outcome(s), the 85 
most appropriate study design (e.g. experimental or quasi- experimental) and the detailed 86 
design features. We make eighteen specific recommendation in three domains: outcomes, 87 
objectives and study design. 88 
Conclusions 89 
Researchers, funders and practitioners will be able to draw on our recommendations to 90 
most efficiently evaluate antimicrobial stewardship interventions.  91 
 92 
  93 
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Background and context 94 
Antimicrobial resistance is a rapidly growing and major threat to human health (1). Overuse 95 
of antimicrobials drives resistance at the individual (2) and population level (3). The term 96 
antimicrobial stewardship refers to interventions and programmes which aim to optimise 97 
antimicrobial use; achieving effective treatment while minimising antimicrobial-associated 98 
harms including resistance (4).  99 
Despite the large and exponentially increasing number of studies published since the term 100 
Antimicrobial Stewardship was coined (5-7), evidence remains remarkably weak both for 101 
what specific antimicrobial use interventions are effective (in terms of mortality, length of 102 
stay, adverse events, resistance rates) and how antimicrobial use improvement strategies 103 
can be implemented to deliver the desired antimicrobial use in daily clinical practice (8). A 104 
2016 systematic review of evidence supporting key antimicrobial use interventions (e.g. 105 
prescribing according to guidelines, de-escalation of therapy, intravenous to oral switching) 106 
identified predominantly low-quality and highly heterogenous supporting evidence (9). The 107 
evidence around improvement strategies is similarly weak, dominated by uncontrolled 108 
before-after studies and inadequately performed interrupted time series analyses, mostly 109 
performed within single hospitals (10).  110 
We recently reported a broad systematic review of antimicrobial stewardship intervention 111 
studies which highlighted key frequent design weaknesses (7). Studies which aim to assess 112 
effectiveness of antimicrobial use interventions are typically under powered and fail to 113 
provide evidence on safety or even do not report clinical outcome data at all. Improvement 114 
strategy studies are often multifaceted with inadequate process evaluation to allow 115 
mediators of impact to be assessed (11). Generally, the field of antimicrobial stewardship 116 
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research is dominated by single-centre observational and quasi-experimental studies which 117 
fail to deal optimally with risks of different forms of bias and that lack external validity (7, 8). 118 
Building on this work we established a working group of investigators in this field which 119 
used a consensus-building iterative process over 12 months to build a conceptual 120 
framework and develop specific recommendations for the design of stewardship 121 
evaluations, which were then reviewed and amended by an expert advisory committee. This 122 
guidance is the final result of that process and aims to support investigators when making 123 
key design decisions and funders assessing proposals for studies of antimicrobial 124 
stewardship interventions and hopefully enhances the quality and impact of research in this 125 
crucial area. 126 
Methods 127 
An international working group for design of antimicrobial stewardship intervention 128 
evaluations was convened in response to the fourth call for leading expert network 129 
proposals by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). The 130 
study sponsor was the UK Medical Research Council. The working group co-ordinators 131 
(MJMB, MJL) and co-applicants (VAS, ASW and CHvW) purposively selected an additional 132 
eight leading clinical and academic specialists in antimicrobial stewardship and clinical trial 133 
design from six European countries (France, Germany, Italy, the Netherlands, Spain, 134 
Switzerland and the UK) to contribute. Selection secured input from the diversity of 135 
professionals involved in antimicrobial stewardship practice (infection, internal medicine, 136 
intensive care medicine) and research (trial design, statistics and qualitative research) 137 
disciplines. Consensus was sought through a nominal group process. Group members 138 
completed a structured questionnaire to establish the scope of work, key study designs 139 
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used in antimicrobial stewardship, identify the major limitations on different study designs 140 
and key issues to develop ahead of a first face-to-face meeting. The group met in March 141 
2017 and anonymised responses were feedback to the whole group and relevant literature 142 
was presented (VAS, CHvW, MJL). This identified the need for a comprehensive systematic 143 
review of study designs in the literature. In parallel, in moderated small group work, 144 
candidate solutions were proposed to address the limitations identified, and in a final 145 
round-table moderated discussion the group prioritised four key areas where research 146 
design considerations restrict translation of findings into practice: features of the 147 
intervention under evaluation; appropriate selection of outcome measures; demonstration 148 
of superiority / non-inferiority of the intervention according to the outcome measures 149 
selected and strategies to minimise bias within experimental and quasi-experimental study 150 
designs. The working group’s initial outputs were reviewed by two independent advisory 151 
experts, both senior, clinically active antimicrobial stewardship experts in different 152 
European countries. Their input prompted widening the group to bring in  additional 153 
expertise in the field of implementation research, primary care and paediatrics. A second 154 
face-to-face meeting the working group used the findings of the systematic review to 155 
develop a theoretical framework through which researchers can address these four key 156 
research design considerations. The group proposed a series of key questions researchers 157 
can use to highlight the major issues they need to address to arrive at an optimal design for 158 
their specific research project. Final agreement of recommendations presented here by all 159 
eighteen members of the working group was achieved by email. 160 
 161 
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A THEORETICAL FRAMEWORK FOR DESIGNING ANTIMICROBIAL STEWARDSHIP 162 
EVALUATIONS 163 
The impact of intervention design 164 
Detailed discussion of how antimicrobial stewardship interventions are designed is beyond 165 
the scope of this guidance. However, the design of the scientific evaluation of an 166 
intervention depends on how that intervention was designed, and this then may depend on 167 
a set of interdependent considerations (Figure 1a). The intervention rationale should 168 
include its basis in theory and existing evidence. (Table 1 is a glossary of terms used in this 169 
guidance). The existing evidence that informed the research question should be clearly 170 
explained on an efficacy-effectiveness-implementation spectrum (12), as these 171 
considerations will determine how outcomes are selected and prioritized (Figure 1b). 172 
Detailed characterization of the intervention setting is required to allow assessment of 173 
external validity and to minimize selection bias. Stewardship interventions are typically 174 
multifaceted and each intervention feature must be specified precisely. The same holds for 175 
how the intervention’s impact will be determined; this will influence definition and selection 176 
of outcomes, selection of clusters/sites and feasibility of blinding. The intervention aims will 177 
be informed by the rationale and setting and will also be key to selecting the primary and 178 
secondary outcomes; whether these will determine effectiveness and safety or how 179 
implementation results change antimicrobial use and what data are required to support 180 
translation of study findings into practice. These considerations will inform whether the 181 
research sets out to determine superiority or non-inferiority of the intervention measured 182 
by its primary outcome(s) against standard practice and the detectable effect sizes/non-183 
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inferiority margins, the most appropriate study design (e.g. experimental or quasi- 184 
experimental) and the detailed design features. 185 
  186 
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Recommendations regarding selection of outcome measures 187 
When assessing the impact of a stewardship intervention, researchers should aim to 188 
consider all intended and potential unintended effects (13-15). Outcome measures can be 189 
helpfully grouped into three domains as clinical (typically to assess safety of an 190 
antimicrobial-sparing intervention in terms of patient outcome), microbiological 191 
(resistance), and care-related (processes and structures of care, sometimes referred to as 192 
quality or performance outcomes) (16) (table 2). Whether the study is primarily assessing 193 
effectiveness, implementation or a combination of both, will determine how outcomes are 194 
selected and prioritised, but, in general, appropriate outcome measures should be 195 
prospectively defined from each of the three domains. It is essential to recognise that whilst 196 
individually randomised efficacy trials aim to avoid selection bias, the inevitably restricted 197 
populations that enter such trials can potentially lead to generalisability bias, making 198 
extrapolation to wider populations challenging. While stewardship studies typically assess 199 
interventions made at the cluster level, assessment of clinical, microbiological and care 200 
related outcomes is often possible at an individual patient level and should be included 201 
where possible to address this.  202 
Clinical outcomes are missing from many published stewardship studies. In fact, most of 203 
these studies were not sufficiently powered to exclude clinically meaningful harm. Concern 204 
that this prevents adoption of antimicrobial reduction strategies into practice has led some 205 
to call for routine use of co-primary clinical outcomes in stewardship evaluations (17). The 206 
working group felt that clinical outcome measures should always be pre-specified and 207 
reported. Exceptions could be implementation studies of interventions for which concerns 208 
over safety will not be a barrier to adoption of their findings. 209 
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Microbiological outcomes address the impact of the intervention on antimicrobial 210 
resistance and/or rates of Clostridium difficile infection. A central rationale for antimicrobial 211 
stewardship interventions is that reducing antimicrobial exposure should reduce harm to a 212 
patient’s microbiome and selection for antibiotic resistance. However, the evidence base 213 
remains sparse, and mostly of low quality, with lack of reliable pre-intervention data a 214 
particular limitation (9, 18, 19). Incorporating assessment of colonisation/infection by 215 
resistant organisms within a stewardship study can be challenging as event rates are often 216 
low and the relationship between antimicrobial exposure and resistance may be temporally 217 
distant and complicated by interactions with exposure to resistant pathogens and infection 218 
control measures. The working group agreed that while reductions in antimicrobial 219 
resistance should not be the primary outcome of stewardship studies, measurement of 220 
prevalence or incidence of C. difficile infection and of antimicrobial resistance should be 221 
included in the design where possible, and it should be clear whether measured resistance 222 
is in relation to the infecting pathogen and type of infection or among colonising strains. 223 
Care provision outcome measures (sometimes called quality or performance measures) 224 
include process indicators, prescribing behaviours, and antimicrobial use data. These are 225 
usually relatively straightforward to obtain and are important to gather and report since 226 
clinical outcomes can only be interpreted meaningfully if it is clear that patient management 227 
has truly changed. Process indicators may address prescribing quality (e.g. guideline 228 
adherence or documentation practice) and reveal mediators of observed results. They are 229 
particularly important in implementation research to assess how the intervention under 230 
evaluation was actually delivered across the study (fidelity). This allows distinction between 231 
strategies that do and do not change the behaviours they aim to change and identification 232 
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of those elements of an intervention that are impactful and of barriers for implementation 233 
(11). Gathering appropriate qualitative data (e.g. from service managers, care providers and 234 
patients as appropriate) will allow an intervention’s impact on cultural aspects of antibiotic 235 
use to be evaluated. Process outcomes are needed to assess organisational impact, of both 236 
implementation and long-term sustainability. Sustainability assessment is particularly 237 
important when an intervention has significant organisational-level impact through 238 
diversion of activity or cost (20). For detailed consideration of these issues researchers 239 
should consult current guidance on development and evaluation of complex interventions 240 
(21). 241 
Timing of outcome measurements 242 
Within each domain of outcome measure, consideration must be given to appropriate 243 
timing depending on the nature of the intervention and population (e.g. long and short term 244 
mortality, clinical complications during hospitalisation or after discharge). Timing of 245 
measurement of microbiological outcomes should be considered to assess impact on 246 
resistance including C. difficile and timing of process outcome measurements should be 247 
considered to assess long-term sustainability.  248 
 249 
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 250 
Establishing superiority or non-inferiority 251 
Where a stewardship study sets out to establish the effectiveness of an intervention, 252 
incorporation of appropriate controls is essential if the results are to inform practice, 253 
irrespective of whether an experimental or non-experimental design is used (see below). 254 
Researchers need to decide whether their primary objective is to determine superiority or 255 
non-inferiority of the intervention vs control.  256 
Interventions aiming to improve treatment outcome. In some situations, a relevant clinical 257 
benefit can be hypothesised for an intervention (e.g. an intervention that focuses on 258 
increasing earlier targeted treatment based on test results or preventing under-treatment) 259 
and a study assessing the effectiveness of the intervention would seek superiority of the 260 
intervention vs. control for an appropriate primary clinical outcome.  261 
Intervention aims to reduce antimicrobial exposure. In most situations, stewardship 262 
interventions aim to preserve clinical outcome while reducing unnecessary antimicrobial 263 
exposure (e.g. less inappropriate initiation of antibiotics, choice of narrower spectrum or 264 
shorter duration) and improving quality of prescribing. As a result there is often some 265 
degree of real or perceived risk of patient-level harm, which may be specific to the 266 
intervention, patient population, setting and disease. Researchers designing effectiveness 267 
evaluations should consider what potential for patient harm would prevent adoption of the 268 
intervention even if it were effective in reducing antimicrobial exposure. Researchers 269 
should select appropriate secondary clinical endpoint(s) to address this concern. Ideally in 270 
this situation the research should seek both superiority for an appropriate process measure 271 
and non-inferiority (i.e. not qualitatively worse than control) for a co-primary clinical 272 
outcome. The key measure to assess non-inferiority is the non-inferiority margin, being the 273 
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smallest outcome difference for which the intervention would be considered no worse than 274 
control. The size of the non-inferiority margin strongly influences the sample size required 275 
to demonstrate non-inferiority with sufficient power. What margin is chosen depends on 276 
the outcome selected. The margin needs to be small enough to exclude relevant harm, 277 
which would prevent intervention implementation into practice. Researchers should justify 278 
the non-inferiority margin chosen with regard to severity and frequency of the outcome in 279 
the control group (which may, for example be affected by case-mix (22).  280 
Naturally, trials designed for demonstrating non-inferiority of clinical outcomes usually 281 
require large sample sizes. In such trials an interim analysis of a process outcome could be 282 
used to determine futility; if the intervention does not lead to the pursued process change 283 
continuing that intervention may not be logical, as non-inferiority will be the inevitable 284 
outcome.  285 
Recognising that achieving adequate power to exclude clinically relevant non-inferiority will 286 
not always be feasible, the group felt that researchers should at least specify and report 287 
point estimates and confidence intervals for a single prespecified lead clinical outcome. 288 
Bayesian analyses may be helpful to directly estimate the probability that intervention is 289 
more than 2.5%, 5%, 7.5% etc inferior to control (23). Researchers should also prespecify 290 
the clinical outcomes they will use to assess the safety of the intervention, and all available 291 
clinical outcome data should be reported, in order to allow future meta-analysis. 292 
Unavailability of data should be explained. Unplanned exploratory analyses of clinical 293 
outcomes should be reported as such.  294 
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In studies addressing how interventions with established efficacy should be implemented, 295 
the quantitative outcome measures will be predominantly process measures and 296 
comparisons will seek to determine superiority of the intervention over comparator.  297 
Sample size calculations 298 
Studies evaluating effectiveness of an antimicrobial intervention need to be powered to 299 
demonstrate clinically relevant non-inferiority. In a superiority trial, detecting a large effect 300 
with high probability is almost always possible at a feasible sample size. Whereas 301 
demonstrating superiority only requires the confidence interval for the effect estimate to 302 
exclude zero, regardless of its width, determining non-inferiority requires the entire 303 
confidence interval to lie below the non-inferiority margin (24). As a result, much larger 304 
participant numbers are usually required to demonstrate non-inferiority within clinically 305 
relevant margins which may be very small and difficult to define for outcomes such as 306 
mortality (25). This difference lies in that superiority trials tend to be powered on an 307 
expected effect, which is often larger than what would be deemed a clinically relevant 308 
effect, whereas non-inferiority trials need to be powered on a clinically relevant effect. 309 
One proposed solution to this issue is the Desirability of Outcome Ranking (DOOR)/ 310 
Response Adjusted for Days of Antibiotic Risk (RADAR) approach which uses investigator 311 
ranked composite outcomes. This approach is based on the assumption that the same 312 
outcome with less antimicrobial exposure is desirable (26). Yet, problems with clinical 313 
interpretation and sensitivity to the clinical outcomes chosen have been reported (27, 28). It 314 
remains to be determined to what extent the RADAR approach can robustly establish the 315 
effectiveness of novel stewardship interventions.  316 
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Interrupted time series studies require enough sequential measures before and after the 317 
intervention; the study’s power will depend on the number of data points, their distribution, 318 
variability, the expected strength of the intervention effect and confounding factors such as 319 
seasonality (29), and therefore there are no straightforward sample size formulae. 320 
Researchers should consider the minimal requirements set out in the Cochrane Effective 321 
Practice and Organisation of Care (EPOC) resources (30).  322 
Study design 323 
Stewardship interventions typically target prescribers/professionals rather than individual 324 
patients. As a consequence, evaluations involving individual patient randomisation are 325 
usually not possible because of contamination. Instead, intervention allocation must be 326 
clustered (e.g. hospital, ward, primary care practice, or physician). An important advantage 327 
of allocation at the cluster level is that it is more representative of real-life clinical practice. 328 
It is therefore more suited to studying both antimicrobial use interventions and 329 
antimicrobial improvement strategies rather than efficacy. Whereas in individual patient 330 
trials, randomisation can be expected to control for confounding bias and maximise internal 331 
validity, with cluster randomised controlled trials (cRCT), researchers need to give careful 332 
consideration to how clusters are defined and characterised. Clusters should be defined at 333 
the lowest level (e.g. clinical team, ward, practice, hospital) where contamination is unlikely 334 
as this will maximise the number of available clusters and hence study power. However, 335 
with the small number of clusters typically available in stewardship evaluations, 336 
randomisation cannot be relied on to avoid imbalance between intervention and control 337 
clusters. Therefore baseline imbalances which may influence the intervention’s impact (e.g. 338 
antimicrobial use, antimicrobial resistance rates, infection control standards, antimicrobial 339 
stewardship structures and processes, case-mix of patients) should be specified a priori and 340 
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data on these should be gathered for inclusion in multivariate analyses. Baseline imbalance 341 
in factors which a strong association with outcome or that could potentially modify the 342 
effect of the intervention can be addressed through stratified randomisation (e.g. putting 343 
clusters into similar pairs and allocating one of each pair randomly to intervention vs 344 
control), or use of a cross-over design (see below). Cluster characterisation is also essential 345 
to understand any observed heterogeneity of the intervention’s effect between clusters. It 346 
optimises external validity by allowing others to judge the representativeness for their 347 
clinical practice and to understand the logistical challenges of implementation.  348 
Experimental study designs (Table 3) 349 
Three main forms of cluster-randomised design may be appropriate depending on the 350 
intervention. As above, parallel cRCTs, in which each cluster is randomised to either the 351 
intervention or control, minimise risk of contamination and maximise independence of the 352 
intervention from cluster-level characteristics. In some situations, perceptions of the 353 
intervention may influence whether clusters are willing to be randomised to control or 354 
intervention arms and hamper participation or introduce bias. Stepped-wedge cRCTs 355 
(swcRCTs) overcome this issue since all clusters receive the intervention during the trial, and 356 
allow estimation of the intervention effect within each cluster. swcRCTs can be logistically 357 
challenging to deliver since some clusters may have to wait to introduce the intervention 358 
and exposure should be avoided. Furthermore, the analysis of swcRCT is more complex (31). 359 
Randomisation of time of implementation is crucial to ensure independence of the timing of 360 
introduction from cluster-level factors. Cross-over cRCTs offer the potential to estimate 361 
intervention effects in both directions – i.e. introducing and withdrawing, but may not be 362 
practicable (e.g. it may not be feasible to withdraw an educational intervention. 363 
Alternatively, the washout phase of a cross-over study may be considered an assessment of 364 
  19
sustainability for some forms of intervention. Assessment of carried antimicrobial resistance 365 
in crossover designs may need to consider the potential for resistance selection to persist. 366 
A particular challenge with evaluation of interventions made at a cluster rather than 367 
patient-level is intracluster correlation (32). This must be incorporated into the sample size 368 
calculation otherwise a trial may be underpowered. Intracluster correlation is the extent to 369 
which patients are more similar to each other within a cluster than they would be if selected 370 
at random. The intracluster correlation coefficient (ICC) of an outcome is a measure of the 371 
relatedness of clustered data by comparing the variance within clusters (e.g. hospitals) with 372 
the variance between clusters. A high ICC means that observations within clusters are much 373 
more similar to each other than to observations in other clusters, while an ICC of zero 374 
means that observations within one cluster are equally similar to each other than to 375 
observations in other clusters. In general, if the ICC is large, research designs with cross-over 376 
are more efficient, while if the ICC is low, parallel cluster designs are more efficient (32). 377 
Quasi-experimental study designs (Table 4) 378 
In situations where randomisation is not feasible or ethically not acceptable (see below), 379 
quasi-experimental, before-after-studies have the potential to deliver robust evidence of a 380 
causal relationship between an intervention and measured outcomes if they incorporate 381 
appropriate controls and analyses which account for time trends. Where control is provided 382 
through comparison with centre(s) where the intervention is not introduced, the term 383 
Controlled Before-After (CBA) study is used. Where control is provided by use of pre-384 
intervention observations within centres, and secular time-trends in the outcomes are 385 
specifically accounted for, the term Interrupted Time Series (ITS) study is used. In practice, 386 
ITS reflects a method of analysis, being used for before and after studies and CBA, rather 387 
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than a specific study type and can also be applied to CBA studies. CBA studies which do not 388 
control for time-trends are unlikely to provide reliable evidence, regardless of external 389 
control (19). The working group agreed that, design of quasi-experimental evaluations of 390 
stewardship interventions must always account for changes in time (33, 34). Such analyses 391 
require sufficient pre-intervention time points to incorporate segmented regression 392 
analysis, and should consider adjustment for autocorrelation (e.g. using ARIMA models). 393 
Such analyses should report immediate effects on outcome and trends before and after the 394 
implementation, and assess whether trends are non-linear (29, 35). Furthermore the timing 395 
of intervention implementation must be externally set to avoid the problem of regression to 396 
the mean which occurs when sites introduce a stewardship intervention in response to 397 
deterioration in the chosen outcome measure. Detailed guidance on conduct of Interrupted 398 
Time Series analyses are available through EPOC (30) and described in a recent review (36). 399 
Ethical considerations 400 
Antimicrobial stewardship measures which balance immediate and individual risks against 401 
future and societal access to effective antimicrobials raise challenging ethical issues around 402 
intergenerational justice, global distributive justice and protection of public health (37). A 403 
key ethical issue in stewardship research is that, by gathering evidence for safety through 404 
clinical outcome measures, the possibility of individual harm is acknowledged. Individual 405 
patient consent may not be feasible in studies of interventions which act on prescribers or 406 
structures such as hospitals or clinics. This may set a higher ethical barrier than for 407 
individually randomized studies in which informed consent can be obtained. In this situation 408 
the research design process should involve patients to ensure that independent non-409 
research views from the relevant patient population about these trade-offs are heard, 410 
actively considered, and incorporated into the final design. Additionally, researchers should 411 
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be able to justify why the interventions under examination are reasonable choices of 412 
practice which could also be made outside the study setting. Studies in which the 413 
intervention is made at a cluster level will often still use individual patient data. Any 414 
requirement for individual patient consent to collect data may lead to loss of 415 
representativeness and a biased assessment of the intervention effect. Because consent is 416 
acquired with knowledge of the intervention, there is an increased risk of selection bias, e.g. 417 
if investigators are more motivated to enroll patients during the intervention period. 418 
Depending on the national regulations, in some countries study designs can address this 419 
issue through use of de-identified or anonymous data (e.g. through electronic patient 420 
records) of parameters collected routinely in clinical practice without the need for individual 421 
patient consent. 422 
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 423 
KEY DESIGN DECISIONS 424 
The consensus group considered that researchers planning antimicrobial stewardship 425 
evaluations must make a set of key decisions (Table 5) which will ultimately determine 426 
optimal study design. We have classified these decisions based on whether they apply to 427 
the intervention itself, the evaluation setting, the outcomes of interest, the research 428 
objective and type of study. Detailed explanation of the decisions are presented in 429 
supplementary materials. 430 
DISCUSSION AND CONCLUSIONS 431 
The theoretical framework and design recommendations we present have been developed 432 
by a diverse international working group with broad and substantial expertise in 433 
antimicrobial stewardship research and practice. They address aspects of study design 434 
which are crucial to translation of research into practice and will, we believe, increase the 435 
impact of future research in this field. By drawing on wide-expertise and building our 436 
comprehensive systematic review we consider our recommendations relevant across 437 
diverse settings of care. Our work has some notable limitations. Although we gave careful 438 
consideration to the breadth of expertise required on the group and sought external advice, 439 
we did not seek lay input. We cannot discount the possibility that this would have changed 440 
our emphasis, around patient reported outcome or experience measures for example. Given 441 
the technical nature of our guidance we think it unlikely this would have changed our 442 
conclusions. An inherent risk of the consensus-group design is ’group think’ in which 443 
members trying to reach consensus fail to critically evaluate alternative views. To address 444 
this we sought critical evaluation by two highly eminent international experts in this field. 445 
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Although these were also, of necessity, experts in antimicrobial stewardship research, the 446 
impact of their input on our thinking, the breadth and seniority of expertise in our group 447 
make it unlikely we have failed to consider major alternative viewpoints. Notwithstanding 448 
these caveats, we believe that application of this guidance has the potential to greatly 449 
improve the quality and impact of antimicrobial stewardship research.  450 
 451 
 452 
SUMMARY RECOMMENDATIONS 453 
Outcomes 454 
• Researchers should determine whether their study aims to investigate, 455 
effectiveness, or implementation (‘what or ‘how’). This will determine the priority 456 
and nature of outcomes. 457 
• All antimicrobial stewardship studies should define process, clinical and 458 
microbiological outcomes and specify a primary process outcome(s) to measure 459 
effectiveness of the intervention.  460 
• Unless there is pre-existing evidence that a stewardship intervention cannot or will 461 
not compromise treatment outcome, an evaluation should attempt to pre-specify a 462 
co-primary clinical/microbiological efficacy outcome on which the study is 463 
adequately powered, or, at minimum, a single lead clinical outcome. 464 
• Clinical and microbiological data documenting treatment outcome should be 465 
collected and reported as pre-specified secondary outcomes even if the study is not 466 
powered on them 467 
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• Measurement of incidence of infections / colonisation due to multi-drug resistant 468 
bacteria and infections due to C. difficile infection should be included in the design of 469 
stewardship interventions whenever possible. Studies assessing resistance should 470 
clarify whether this is related to the infecting pathogen or among colonisers. 471 
 472 
Objectives 473 
• If a relevant clinical benefit can be hypothesised for an intervention, then the 474 
research objective should seek superiority for an appropriate primary clinical 475 
outcome.  476 
• If not, researchers should seek both superiority for an appropriate process measure 477 
and ideally non-inferiority for a co-primary clinical/clinically relevant microbiological 478 
outcome.  479 
• Researchers should justify how the non-inferiority margin has been selected and 480 
balanced against research costs and feasibility. 481 
• Where this is not possible, as a minimum, researchers should specify, and report 482 
point estimates and confidence intervals for, at minimum, a single pre-specified lead 483 
clinical outcome. 484 
• In situations where the study size is determined by a co-primary non-inferiority 485 
safety outcome, an interim futility analysis of the superiority process outcome 486 
should be considered to confirm a relevant change in treatment/management. 487 
 488 
Study design 489 
• Cluster randomised controlled trials (including crossover and stepped-wedge 490 
designs) are preferable to quasi-experimental before/after studies. 491 
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• The threshold for defining clusters should be as low as possible to minimise 492 
contamination, allowing the maximum number of clusters to be studied. 493 
• In a parallel cluster RCT, randomisation should not be relied on to control for 494 
imbalance between study arms if the number of clusters is <20 per arm and 495 
stratified or matched randomisation should be considered 496 
• Designs using within-cluster comparisons (stepped-wedge cRCT, cross-over cRCT or 497 
quasi-experimental approaches) are indicated where there are fewer than 10 498 
clusters per arm. 499 
• Quasi-experimental studies should incorporate appropriate controls and analyses to 500 
account for time trends 501 
• In quasi-experimental studies, timing of the intervention should be externally set or 502 
if this is not possible timing should be explained and described.  503 
• Segmented regression analysis of interrupted time series studies should include 12 504 
time points with at least 100 observations per time point before and after the 505 
intervention to allow for anticipated secular trends and test or correct for 506 
autocorrelation. 507 
• Single centre studies using a robustly designed and analysed interrupted time series 508 
approach including observations before and after the intervention should be 509 
considered the lowest quality research design which will impact on clinical practice. 510 
 511 
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Table 1 Glossary of terms 
Term Explanation  
Intervention rationale The theory and evidence behind the stewardship intervention 
which is to be evaluated encompassing external factors (e.g. 
behavioural theory, evidence from previous research) and the 
clinical setting. 
Clinical setting The environment in which the intervention is evaluated, both 
physical (e.g. ICU, emergency room, hospital type, primary care, 
long-term care) and practical (e.g. prescribing practice, team 
structures, staffing, behaviour). 
Intervention aim(s) The improvement being sought (e.g. reduction in inappropriate 
antimicrobial prescribing, reduction in use of specific 
antimicrobial classes or reduced Clostridium difficile infection)? 
Features of the 
intervention 
The different elements which make up a multifaceted 
intervention (e.g. education, decision support). 
Cluster A unit representing a group of smaller components, at which an 
intervention is delivered (e.g. a hospital ward representing all 
the doctors working in it, a group of primary care physicians 
working in a practice) 
Outcomes of interest The outcomes measured to determine effectiveness, safety and 
costs of the intervention. 
Experimental design 
studies 
Studies which use randomisation to allocate the stewardship 
intervention and control, either to individual 
patients/professionnals or clusters of patients/professionals. 
Quasi-experimental 
design studies 
Studies which don’t use randomisation to allocate the 
stewardship intervention but rather use as controls different 
time period(s) and/or site (s), either external (controlled 
before-after studies) or internal (interrupted time series 
analyses, before-after studies). 
Contamination Unintended exposure of patients in the control phase or cluster 
to some or all of the intervention. 
Efficacy study A study which assesses whether an antimicrobial use 
intervention produces the expected result under ideal and 
controlled conditions. 
Effectiveness study A study which assesses whether an antimicrobial use 
intervention produces the expected result under 'real-world' 
pragmatic conditions.  
Implementation Study A study which assesses the impact of an antimicrobial use 
improvement strategy in daily practice  
Mediator analyses Techniques to investigate mechanisms through which complex 
interventions achieve an observed effect 
Superiority analysis An analysis which sets out to determine if the intervention or 
strategy being assessed is better than comparator 
Non-inferiority analysis An analysis which sets out to determine whether the 
intervention or strategy being assessed not worse (by a 
prespecified amount, the non-inferiority margin) than 
  2
comparator 
Process Indicators Measures of the care that is actually delivered to the patients 
(e.g., empirical regimen according to guidleine) 
 
Structure indicators  Measures of the organization of the healthcare system (e.g., 
the availability of a stewardship team) 
Ecological assessment 
(of antimicrobial 
resistance) 
Measurement of burden if antimicrobial resistant organism(s) 
or gene(s) in the environment or aggregated patient samples 
  
  3
 
Table 2: Outcome measures in antimicrobial stewardship evaluations 
Clinical outcome measures;  
Examples Notes 
Clinical cure, clinical failure, time to   
clinical response, recurrence rate. 
Mortality, length of stay, need for 
escalation of care (e.g. from ward to 
high dependency or critical care), 
(re)admission to hospital, revisits 
Patient reported outcomes (e.g. 
quality of life measures). 
Typically used to determine the safety of the intervention in 
terms of patient treatment outcome. 
May include microbiological evidence of clinical outcome (e.g. 
microbiological cure or recurrence). 
Most are directly relevant to the individual patient.  
Important safety outcomes which are relatively easy to gather 
at cluster-level, but may only be linked partially to the 
intervention and may be a long way down the patient pathway. 
Adverse drug reactions, drug–drug 
interactions 
Gathering relevant data may require individual consent but 
could be from a subset of patients or use anonymised electronic 
records. 
Microbiological (resistance) outcome measures 
Examples Notes 
Colonisation by antimicrobial resistant 
pathogens (e.g. MRSA or multi-drug 
resistant (MDR) Enterobacteriaceae) 
 
Valuable as short-term surrogate measures of antimicrobial 
resistance-related harm but relevance to individual patients is 
indirect through risk of antimicrobial resistant infection in the 
future or through transmission. 
Ecological assessments may be more feasible than individual 
patient-level measurement. 
Infection by specific organisms (C. 
difficile, antimicrobial resistant 
bacteria) 
Outcome directly relevant to the impact of the antimicrobial 
intervention on the individual patient but uncommon and may 
require long follow-up beyond that needed for clinical outomes  
Care provision (quality or performance) outcome measures 
Examples Notes 
Drug use (e.g. Defined daily doses 
(DDD) or Days of Therapy (DOT) per 
admission or per bed-day 
Appropriateness of treatment (e.g. 
proportion of prescriptions in 
accordance with guidelines)  
Measures of intervention (e.g. 
recommendations given, use of 
clinical  decision support) 
Resource requirements (e.g. staff 
time,  clinical consultations, diagnostic 
Measurement of antimicrobial use (e.g. volume, range of 
agents) used to determine whether the intervention has 
potential to have an effect on clinical or microbiological 
outcomes (if no impact on process, then no 
clinical/microbiological impact by definition) 
Can be selected to measure appropriateness of antimicrobial 
selection 
Important for health-economic analyses and assessment of 
sustainability 
Important for mediator analyses. 
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testing) 
Costs measures  
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Table 3. Design recommendations for experimental evaluations antimicrobial stewardship Interventions 
 
Feature Recommendations 
Parallel cRCTs 
 
Stepped-wedge cRCTs Crossover cRCTs 
Cluster selection Randomised implementation at the lowest level (e.g. prescriber, ward, hospital, primary care practice) at which 
contamination can be minimised 
Define eligibility criteria and document representativeness of included clusters with respect to system from which 
they are drawn (e.g. size, case mix) 
Cluster allocation and 
randomisation, timing 
of intervention 
Ensure allocation concealment until the intervention is 
implemented (as complete blinding to allocation after 
randomisation is often not feasible). 
Conceal timing and order of intervention / cross-over 
as much as possible 
Timing of intervention should be determined externally 
and at random, where possible 
Cluster balance Pursue good/excellent balance between clusters (e.g. 
matching, stratified randomisation based on factors 
likely to be associated with the outcome under study). 
No lower limit above which randomisation will ensure 
balance but particularly problematic if there are fewer 
than 20 clusters per randomised group.  
Collect data to document balance between clusters.  
Good/excellent balance between clusters achieved 
through design. 
Blinding Consider the objectivity of the selected outcomes and the extent to which patients and assessors of outcomes 
can be blinded to the cluster allocation 
Outcomes Specify a primary or co-primary process outcome 
Specify a co-primary clinical outcome or at minimum one lead clinical outcome, and specify and report secondary 
clinical outcomes even if not powered on these 
Specify and analyse outcomes in each domain – clinical, microbiological, process (quantity or quality of 
antimicrobial use) 
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Within implementation research, process outcomes should be selected with regard to complex intervention 
methodology [21] e.g. measures of fidelity, mediators and modifiers of the intended effect and measures of 
organisational impact 
Consider all important harms / unintended effects including ‘squeezing the balloon’ effects in which achieving the 
intended reduction in antimicrobial overuse results in an unintended increase in harmful overuse elsewhere [14, 
15, 38]. 
Define timing of different cluster-level and individual-level outcomes 
Power calculation Provide sample size calculations to demonstrate study power – for the primary / co-primary outcome(s), and 
taking intra-cluster correlation into account 
Analysis Adjust for secular trends (particularly for stepped-wedge cRCTs) 
Selection of patients for 
outcome evaluation 
Ensure robust consistent inclusion of patients in control and intervention clusters / phases.  
Report denominators from whom included patients were selected wherever possible. 
Follow-up of patients Timing of patient follow-up to assess patient-level outcomes should consider relevant timescales for both 
effectiveness and harms 
Follow-up of clusters Consider duration of follow up both for immediate effect of the intervention and 
sustainability  
Only possible with short-
term interventions with 
rapid loss of effect post 
withdrawal 
Reporting Report according to CONSORT criteria for cluster RCTs, stepped-wedge cRCTs, and other CONSORT guidelines as 
appropriate (e.g. pragmatic trials, non-inferiority trials). Consider using the TiDier checklist to clearly describe any 
behavioural intervention [39]. 
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Table 4. Design recommendations for quasi-experimental evaluations antimicrobial 
stewardship Interventions 
 
Feature Recommendations 
Control Even in situations where randomisation is not possible (e.g. too few 
available clusters) allocation to intervention or control group should be 
made externally if at all possible, i.e. not depending on known factors 
or clinician preference 
Consider trying to match controls to minimise risk of bias arising from 
intrinsic differences between control and intervention groups 
Timing Timing of intervention should be externally set OR if this is not possible 
timing must be explained and described 
Data Data from automated electronic data recording (e.g. antimicrobial use 
data, routine electronic patient data) can be used retrospectively for 
pre-intervention data providing that collection/entry is consistent over 
calendar time, otherwise all data should be collected prospectively 
Measure, report and analyse any concurrent changes in case-mix, 
changes in methodology of outcome assessment, and care practices 
Analysis Include at least 12 monthly time points before and after the 
intervention to allow for anticipated secular trends [36, 40] 
Use segmented regression or ARIMA models to account for secular 
trends. 
Include at least 100 observations per time point [40]. 
Check and, if necessary, correct for autocorrelation. 
Outcomes See table 3 
Follow-up of 
patients 
Timing of patient follow-up to assess patient-level outcomes should 
consider relevant timescales for both effectiveness and harms  
Follow-up of 
clusters 
Consider duration of follow up both for immediate effect of the 
intervention and sustainability  
Reporting Report according to relevant recommendations; STROBE-AMS [41] or 
STROBE [42] and the TiDier checklist [39], SQUIRE to describe in detail 
quality improvement component of study [43], TREND statement for 
nonrandomized evaluations of behavioural and public health 
interventions [44]. 
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Table 5. Key Design Decisions. A detailed explanation of the rationale and how these 
address different aspects of design is set out in the supplementary materials 
 
Question Design aspect addressed 
Where does knowledge gap the study aims 
to address lie on a spectrum between 
‘what’ and ‘how’ questions? 
selection and prioritisation of outcomes 
What are the risks of contamination? how clusters will be defined within the 
study. 
Is it possible to remove the intervention 
after it has been implemented? 
what study design will be most appropriate. 
Is the intervention impact threatened by 
sustainability? 
selection and timing of study outcomes 
What forms of bias threaten the validity of 
the study? 
cluster selection; feasibility of blinding; 
data collection 
What features of the evaluation setting will 
impact on external validity? 
cluster selection; feasibility of blinding; 
data collection 
Is it possible to blindly assess the outcome? feasibility of blinding 
 
 
 
Figure 1A.  Interacting considerations relating to the intervention to be evaluated and 
their impact on study design 
 
Figure 1B. An evaluation pipeline for antimicrobial stewardship intervention. Adapted from 
[12]. 
 
 
